Monte Rosa Therapeutics (GLUE) Capital Expenditures (QoQ) (2020 - 2026)
Monte Rosa Therapeutics (GLUE) Capital Expenditures (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Monte Rosa Therapeutics | 2.30 Bn | 1.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,043.45% |
| Dec 31, 2025 | 89.80% |
| Sep 30, 2025 | -195.47% |
| Jun 30, 2025 | 879.61% |
| Mar 31, 2025 | 108.10% |
| Dec 31, 2024 | -1,041.10% |
| Sep 30, 2024 | -83.53% |
| Jun 30, 2024 | 146.49% |
| Mar 31, 2024 | -94.47% |
| Dec 31, 2023 | 223.21% |
| Sep 30, 2023 | -321.48% |
| Jun 30, 2023 | -29.07% |
| Mar 31, 2023 | 12.50% |
| Dec 31, 2022 | 114.14% |
| Sep 30, 2022 | 2,528.28% |
| Jun 30, 2022 | -81.74% |
| Mar 31, 2022 | 163.37% |
| Dec 31, 2021 | -170.16% |
| Sep 30, 2021 | 271.24% |
| Jun 30, 2021 | -189.45% |